N-[4-(4-morpholinyl)butyl]-2-benzofurancarboxamide profile

CL82198: a selective inhibitor of MMP13 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	2777
CHEMBL ID	116757
CHEBI ID	92019
SCHEMBL ID	8343274

Synonym
benzofuran-2-carboxylic acid (4-morpholin-4-yl-butyl)-amide
bdbm50149234
n-(4-morpholinobutyl)benzofuran-2-carboxamide
BRD-K00675675-003-01-2
cl-82198
307002-71-7
NCGC00167801-01
CHEMBL116757 ,
CL 82198 ,
n-[4-(4-morpholinyl)butyl]-2-benzofurancarboxamide
gtpl5170
cl82198
n-[4-(morpholin-4-yl)butyl]-1-benzofuran-2-carboxamide
SCHEMBL8343274
smr004676625
MLS006011944
cl-82198, >=98% (hplc), powder
mfcd12828877
CS-5812
HY-100359
CHEBI:92019
Z435160380
AKOS032953784
Q27076092
benzofuran-2-carboxylic acid (4-morpholin-4-yl-butyl)amide
2-benzofurancarboxamide, n-[4-(4-morpholinyl)butyl]-
AS-76783
DTXSID601024592
E85234

Excerpt	Reference	Relevance
" A compound from this series demonstrated rat oral bioavailability and efficacy in a bovine articular cartilage explant model."	( Identification of potent and selective MMP-13 inhibitors. Collins, E; Du, X; Geck, M; Hotchandani, R; Levin, JI; Lovering, FE; Rush, TS; Skotnicki, J; Wu, J; Xu, ZB, 2005)	0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Class	Description
benzofurans
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	26.3506	0.0013	10.1577	42.8575	AID1259255
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Interstitial collagenase	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0002	0.8502	10.0000	AID109087
Collagenase 3	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0000	0.7675	10.0000	AID109422
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Process	via Protein(s)	Taxonomy
proteolysis	Interstitial collagenase	Homo sapiens (human)
protein metabolic process	Interstitial collagenase	Homo sapiens (human)
extracellular matrix disassembly	Interstitial collagenase	Homo sapiens (human)
collagen catabolic process	Interstitial collagenase	Homo sapiens (human)
positive regulation of protein-containing complex assembly	Interstitial collagenase	Homo sapiens (human)
cellular response to UV-A	Interstitial collagenase	Homo sapiens (human)
extracellular matrix organization	Interstitial collagenase	Homo sapiens (human)
endochondral ossification	Collagenase 3	Homo sapiens (human)
growth plate cartilage development	Collagenase 3	Homo sapiens (human)
proteolysis	Collagenase 3	Homo sapiens (human)
extracellular matrix disassembly	Collagenase 3	Homo sapiens (human)
bone mineralization	Collagenase 3	Homo sapiens (human)
collagen catabolic process	Collagenase 3	Homo sapiens (human)
bone morphogenesis	Collagenase 3	Homo sapiens (human)
response to amyloid-beta	Collagenase 3	Homo sapiens (human)
extracellular matrix organization	Collagenase 3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Process	via Protein(s)	Taxonomy
endopeptidase activity	Interstitial collagenase	Homo sapiens (human)
metalloendopeptidase activity	Interstitial collagenase	Homo sapiens (human)
serine-type endopeptidase activity	Interstitial collagenase	Homo sapiens (human)
peptidase activity	Interstitial collagenase	Homo sapiens (human)
zinc ion binding	Interstitial collagenase	Homo sapiens (human)
endopeptidase activity	Collagenase 3	Homo sapiens (human)
metalloendopeptidase activity	Collagenase 3	Homo sapiens (human)
serine-type endopeptidase activity	Collagenase 3	Homo sapiens (human)
calcium ion binding	Collagenase 3	Homo sapiens (human)
collagen binding	Collagenase 3	Homo sapiens (human)
zinc ion binding	Collagenase 3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Process	via Protein(s)	Taxonomy
extracellular region	Interstitial collagenase	Homo sapiens (human)
extracellular matrix	Interstitial collagenase	Homo sapiens (human)
extracellular space	Interstitial collagenase	Homo sapiens (human)
extracellular region	Collagenase 3	Homo sapiens (human)
extracellular matrix	Collagenase 3	Homo sapiens (human)
extracellular space	Collagenase 3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay ID	Title	Year	Journal	Article
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID493017	Wombat Data for BeliefDocking	2005	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18	Identification of potent and selective MMP-13 inhibitors.
AID109422	Inhibition of Matrix Metalloprotease-13 (MMP-13)	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	Fragment-based drug discovery.
AID241564	Inhibitory concentration against MMP-13 of bovine articular cartilage explants	2005	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18	Identification of potent and selective MMP-13 inhibitors.
AID349394	Inhibition of MMP13 at 10 ug/mL	2008	Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.
AID109087	Inhibition of Matrix Metalloprotease-1 (MMP-1)	2004	Journal of medicinal chemistry, Jul-01, Volume: 47, Issue:14	Fragment-based drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (23.08)	29.6817
2010's	4 (30.77)	24.3611
2020's	6 (46.15)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (15.38%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (84.62%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
indole [no description available]	3.12	1	indole; polycyclic heteroarene	Escherichia coli metabolite
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	3.12	1	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
abt 702 [no description available]	3.12	1	bipyridines
acetohydroxamic acid acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.	3.12	1	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	3.12	1	aminobenzoic acid; phenols	antitubercular agent
hydroxyproline Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.. hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.	2.21	1	4-hydroxyproline; L-alpha-amino acid zwitterion	human metabolite; mouse metabolite; plant metabolite
4-phenylphenol 4-phenylphenol: RN given refers to cpd without isomeric designation. biphenyl-4-ol : A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4.	3.12	1	hydroxybiphenyls
benzanilide [no description available]	3.12	1
1,4-benzodioxan 1,4-benzodioxan: structure in first source	3.12	1
hadacidin hadacidin: inhibitor of AMP synthesis; RN given refers to parent cpd; structure. hadacidin : A monocarboxylic acid that is N-hydroxyglycine in which the hydrogen attached to the nitrogen is replaced by a formyl group. It was originally isolated from cultures of Penicillium frequentans.	3.12	1	aldehyde; monocarboxylic acid; N-hydroxy-alpha-amino-acid	antimicrobial agent; antineoplastic agent; Penicillium metabolite; teratogenic agent
4-phenylbenzoic acid 4-phenylbenzoic acid: RN given refers to 4-carboxylic cpd	3.12	1
benzo(b)thiophene-2-carboxylic acid benzo(b)thiophene-2-carboxylic acid: for prevention of osteoporosis; structure given in first source	3.12	1
propidium iodide [no description available]	3.12	1	organic iodide salt
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.61	2
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	3.12	1	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide : A leucine derivative obtained by fpormal condensation of the secondary amino group of 5-({2,3-dichloro-4-[1-methyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)-2-furoic acid and the carboxy group of N-amidino-L-leucylglycine	3.12	1	D-leucine derivative; dichlorobenzene; furoic acid; glycine derivative; guanidines; pyrazolylpiperidine
ik 682 IK 682: inhibits TNF-alpha converting enzyme; structure in first source	3.14	1	hydroxamic acid; pyrrolidin-2-ones; quinolines
cp 91149 CP 91149: inhibits liver glycogen phosphorylase; structure in first source	3.12	1
abt-770 ABT-770: structure in first source	3.14	1
sb 3ct compound SB 3CT compound: a matrix metalloproteinase-2 inhibitor; structure in first source	3.14	1	aromatic ether
arp-100 [no description available]	3.14	1
bms-566394 BMS-566394: structure in first source	3.14	1
incb3619 INCB3619: ADAM inhibitor; structure in first source	3.14	1
5,10-methylenetetrahydrofolic acid 5,10-methylenetetrahydrofolic acid: RN refers to parent cpd(L-Glu)-isomer	3.12	1	benzamides; methylenetetrahydrofolic acid

Condition	Relationship Strength	Studies
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.02	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.63	2
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Cognitive Decline [description not available]	2.21	1
Acute Confusional Senile Dementia [description not available]	2.21	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.21	1
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.21	1
Cirrhosis [description not available]	2.21	1
Ureteral Obstruction Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.	2.21	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.21	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.21	1

N-[4-(4-morpholinyl)butyl]-2-benzofurancarboxamide

Description

Cross-References

Synonyms (29)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (12)

Molecular Functions (7)

Ceullar Components (3)

Bioassays (35)

Research

Studies (13)

Market Indicators

Research Demand Index: 12.25

Study Types

N-[4-(4-morpholinyl)butyl]-2-benzofurancarboxamide

Description

Cross-References

Synonyms (29)

Research Excerpts

Bioavailability

Drug Classes (1)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (12)

Molecular Functions (7)

Ceullar Components (3)

Bioassays (35)

Research

Studies (13)

Market Indicators

Research Demand Index: 12.25

Study Types

Related Drugs (24)

Related Conditions (12)